ClinicalTrials.gg
CompletedNCT00875550Updated Aug 14, 2015Results posted

Study Evaluating Safety and Efficacy of Dexmedetomidine (DEX) in Intubated and Mechanically Ventilated Pediatric Intensive Care Unit (PICU) Subjects

A Phase 3 interventional study of Dexmedetomidine and Midazolam in Sedation, sponsored by Hospira, now a wholly owned subsidiary of Pfizer. Completed at 37 sites in 2 countries. Open to participants aged 1 Month to 16 Years. Per ClinicalTrials.gov, last updated 2015-08-14.

Sponsored by Hospira, now a wholly owned subsidiary of Pfizer (part of Pfizer) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
175
Allocation
Randomized
Ages
1 Month to 16 Years
Sex
All
01

Study summary

The purpose of this study is to evaluate the safety and efficacy of dexmedetomidine (DEX) in intubated and mechanically ventilated pediatric intensive care unit (PICU) subjects. The key study objectives are:

  • To characterize the loading and maintenance dosing of DEX by age group and overall medical condition of pediatric subjects
  • To evaluate the safety and efficacy of loading and maintenance infusions for sedation in initially intubated and mechanically ventilated PICU subjects
  • To explore the exposure-response relationship between dose of DEX and clinical measures of sedation and safety
Read the detailed description

An estimated 175 subjects will be enrolled at approximately 40 investigative sites. Subjects will be divided into two treatment groups to receive either high dose or low dose Dexmedetomidine (DEX). The loading and maintenance doses in both groups will be stratified according to the presence or absence of cardiopulmonary bypass. The level of sedation will be assessed using the University of Michigan Sedation Scale (UMSS). Score 0 (awake/alert); Score 1 (sleepy/responds appropriately); Score 2 (somnolent/arouses to light stimuli); Score 3 (deep sleep/arouses to deeper); Score 4 (unarousable to stimuli).

Based on these scores and clinical judgment, additional sedation with intravenous midazolam will be administered according to the label. The UMSS scores must be documented before the administration of every midazolam (MDZ) dose and within five minutes after each dose of MDZ. Fentanyl or morphine may be administered to treat pain. Subjects may be extubated after beginning of study drug but are not required to be as part of the study.

The efficacy and safety parameters that will be monitored include sedation levels, heart rate, blood pressure and ventilation indicators. Once subjects have met site-specified respiratory criteria, they will undergo tracheal extubation. The dexmedetomidine infusion may be continued during and after extubation if further sedation is required post-extubation. The continuous infusion of dexmedetomidine must be administered for a minimum of 6 hours and a maximum of 24 hours. Sedation levels, heart rate, blood pressure, respiratory rate, ventilator settings, SpO2 and if available transcutaneous carbon dioxide (TcCO2) and/or arterial blood gases (ABG) will be monitored and recorded in the peri-extubation period.

02

Conditions studied

  • Sedation

Keywords

  • Intubated and mechanically ventilated PICU subjects
03

In context

Lead sponsor

Hospira, now a wholly owned subsidiary of Pfizer is the lead sponsor of 28 studies on the registry; none are open to participants now.

First submitted before Hospira became part of Pfizer.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
1 Month to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Initially intubated and mechanically ventilated pediatric subjects (≥1 month [birth age corrected for prematurity] to \<17 years of age) in an intensive care setting. The means by which the subject is intubated may include nasotracheal, endotracheal or via tracheotomy. The subject must be mechanically ventilated prior to and during the commencement of study drug.
  2. Anticipated to require a minimum of 6 hours of continuous intravenous sedation.
  3. (ASA) classification of 1, 2, 3 or 4.
  4. A UMSS score of 1, 2, 3 or 4 at the start of infusion of study drug.
  5. A dose has been established for this subject's age based upon the diagnosis procedures.

    Status post cardiopulmonary bypass (s/p CPB):

    • Low dose group: Loading dose: 0.2 mcg/kg Maintenance dose titration range (0.025-0.5 mcg/kg/hr)
    • High dose group: Loading dose: 0.5 mcg/kg Maintenance dose titration range (0.1-0.7 mcg/kg/hr)

    All other diagnoses:

    • Low dose group: Loading dose: 0.3 mcg/kg Maintenance dose titration range (0.05- 0.5mcg/kg/hr)
    • High dose group: Loading dose: 0.6 mcg/kg Maintenance dose titration range (0.2 - 1.4 mcg/kg/hr)
  6. If female, subject is non-lactating and is either:

    1. Not of , defined as pre-menarche, or surgically sterile due to bilateral tubal ligation, bilateral oophorectomy, or hysterectomy.
    2. Of childbearing potential but is not pregnant at time of baseline.
  7. Subject's parent(s) or legal guardian(s) has/have voluntarily signed and dated the document approved by the Institutional Review Board. Assent will be obtained where age-appropriate and according to state regulations.

Exclusion criteria

Exclusion Criteria:

  1. Pediatric subjects with neurological conditions that prohibit an evaluation of sedation in the opinion of the investigator (e.g. increased intracranial pressure or extensive brain surgery).
  2. The infusion pump minimal capacity cannot accommodate the lowest possible maintenance infusion rate of study drug based on subject's weight.
  3. Subjects with second degree or third degree heart block unless subject has a pacemaker or pacing wires.
  4. Hypotension that persist beyond a 15 min of re-assessments prior to starting study drug:

    • Age 1 month to ≤6 months old: systolic blood pressure (SBP) \<60 (millimeters of mercury) mmHg
    • Age >6 months to \<2 yrs old: SBP \<70 mmHg
    • Age >2 to \<12 yrs old: SBP \<80 mmHg
    • Age >12 to \<17 yrs old: SBP \<90 mmHg
  5. Pre-existing bradycardia that persists beyond a 15 min period of re-assessment prior to starting study drugs:

    • Age 1 month to \<2 months old: HR \<90 beats per min (bpm)
    • Age ≥2 months to \<12 months old: HR \<80 bpm
    • Age ≥12 months to \<2 yrs old: HR \<70 bpm
    • Age ≥ 2 to \<12 yrs old: HR \<60 bpm
    • Age ≥ 12 to \<17 yrs old: HR \<50 bpm
  6. Serum glutamic pyruvic transaminase ()/alanine aminotransferase (ALT): 1 month -12 months: >165 U/L; >12 months to \<17 years: ≥100 U/L.

    Note: Subjects may be rescreened up to 6 hrs prior to study drug infusion (not including subjects undergoing cardiac surgery with CPB).

  7. Subjects who have a known allergy to dexmedetomidine, MDZ, morphine or fentanyl.
  8. Requirement for medications other than DEX, midazolam, morphine or fentanyl for sedation and pain control.
  9. Subjects with immobility form neuromuscular disease, paralysis from administration of neuromuscular blocking agents, spinal cord injury above T5, or subjects with muscle weakness form congenital or systemic medical illness etiologies. Note: subjects who received NMB agents intraoperatively must be, in the Investigator's opinion, free of residual neuromuscular blockade prior to dosing with study drug.
  10. Subjects who have received another drug or device within the past 30 days.
  11. Subjects who have received DEX in a previous investigational trial within the previous 12 weeks.
  12. Subjects who, in the opinion of the investigator, have any other condition where the risks of DEX would be expected to outweigh its benefits (e.g. cardiogenic shock on >2 vasopressors).
  13. Subjects who will require alpha-2 agonists/antagonists listed below within 48 hrs prior to baseline.

Alpha-2 Agonists: Xylazine*, Clonidine (Catapres, Dixarit), Guanfacine (Tenex), Guanabenz (Wytensin), Mivazerol, Guanadrel (Hylorel), Guanethidine (Ismelin) and Methyldopa (Aldomet). * Xylazine is a veterinary product, but has abuse potentIal in humans.

Alpha-2 Antagonists: Corynanthine, Phenoxybenzamine (Dibenzyline), Phentolamine (Regitine, Rogitine), Tolazoline (Priscoline), Yohimbine, Rauwolscine, Idazoxan, Reserpine (Serpasil) and Mirtazapine (Remeron, Remeron Soltab).

Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ASA physical status

The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
175 participants (actual)

Study arms

  • Active comparator
    Dexmedetomidine Low Dose

    Drug: Dexmedetomidine · Drug: Midazolam · Drug: Fentanyl · Drug: Morphine

  • Active comparator
    Dexmedetomidine High dose

    Drug: Dexmedetomidine · Drug: Midazolam · Drug: Fentanyl · Drug: Morphine

Interventions

  • Study drug titrated up or down to maintain target UMSS range.

  • Rescue medication for sedation according to UMSS scores

  • Rescue medication for pain based on UMSS scores

  • Rescue medication for pain based on UMSS scores.

06

What researchers measure

Primary outcomes

  1. Percentage of Subjects That do Not Require Rescue Midazolam (MDZ) for Sedation Based on Achieving and Maintaining a Target University of Michigan Sedation Scale (UMSS) Score of 1 to 3 While Intubated.

    Clinical Score Level of Sedation 0 Awake/Alert 1. Minimally Sedated: Tired/sleepy, appropriate response to verbal conversation and/or sounds. 2. Moderately Sedated: Somnolent/sleeping, easily aroused with light tactile stimulation. 3. Deeply sedated: Deep sleep, arousable only with significant physical stimulation. 4. Unarousable

    Time frame: 6 to 24 hours

Secondary outcomes

  1. Absolute Time on Study Drug That the Subject is in a UMSS Range of 1 to 3 While Intubated

    Time frame: 6 to 24 hours

  2. Absolute Time on Study Drug That the Subject is Out of the Target Sedation Range (UMSS <1 or >3) While Intubated

    Time frame: 6 to 24 hours

  3. Total Amount of Rescue Medication Required for Sedation and Analgesia While Intubated

    Time frame: 6 to 24 hours

  4. Time to First Dose of Rescue Medication for Sedation and Analgesia

    Time frame: 6 to 24 hours

  5. Time to Successful Extubation

    Time frame: 6 to 24 hours

07

Results

Posted Oct 30, 2014

Participant flow

Participant flow — Overall Study
MilestoneDexmedetomidine Low DoseDexmedetomidine High Dose
Started8986
Completed7776
Not completed1210

Outcome measures

PrimaryPercentage of Subjects That do Not Require Rescue Midazolam (MDZ) for Sedation Based on Achieving and Maintaining a Target University of Michigan Sedation Scale (UMSS) Score of 1 to 3 While Intubated.

Clinical Score Level of Sedation 0 Awake/Alert 1. Minimally Sedated: Tired/sleepy, appropriate response to verbal conversation and/or sounds. 2. Moderately Sedated: Somnolent/sleeping, easily aroused with light tactile stimulation. 3. Deeply sedated: Deep sleep, arousable only with significant physical stimulation. 4. Unarousable

Time frame:
6 to 24 hours
Reported as:
Number · Percentage of subjects
Percentage of Subjects That do Not Require Rescue Midazolam (MDZ) for Sedation Based on Achieving and Maintaining a Target University of Michigan Sedation Scale (UMSS) Score of 1 to 3 While Intubated.
Percentage of subjectsDexmedetomidine Low DoseDexmedetomidine High Dose
Percentage of Subjects That do Not Require Rescue Midazolam (MDZ) for Sedation Based on Achieving and Maintaining a Target University of Michigan Sedation Scale (UMSS) Score of 1 to 3 While Intubated.44.654.3
SecondaryAbsolute Time on Study Drug That the Subject is in a UMSS Range of 1 to 3 While Intubated
Time frame:
6 to 24 hours
Reported as:
Median · Hours
Absolute Time on Study Drug That the Subject is in a UMSS Range of 1 to 3 While Intubated
HoursDexmedetomidine Low DoseDexmedetomidine High Dose
Absolute Time on Study Drug That the Subject is in a UMSS Range of 1 to 3 While Intubated17.2 (5 to 24)17.3 (2 to 24)
SecondaryAbsolute Time on Study Drug That the Subject is Out of the Target Sedation Range (UMSS <1 or >3) While Intubated
Time frame:
6 to 24 hours
Reported as:
Median · hours
Absolute Time on Study Drug That the Subject is Out of the Target Sedation Range (UMSS <1 or >3) While Intubated
hoursDexmedetomidine Low DoseDexmedetomidine High Dose
Absolute Time on Study Drug That the Subject is Out of the Target Sedation Range (UMSS <1 or >3) While Intubated1.0 (0 to 10)0.7 (0 to 14)
SecondaryTotal Amount of Rescue Medication Required for Sedation and Analgesia While Intubated
Time frame:
6 to 24 hours
Reported as:
Mean · Milligram
Total Amount of Rescue Medication Required for Sedation and Analgesia While Intubated
MilligramDexmedetomidine Low DoseDexmedetomidine High Dose
Midazolam2.221 ± 4.60891.241 ± 2.3052
Fentanyl45.225 ± 83.774344.367 ± 112.13
Morphine1.446 ± 3.29781.141 ± 2.4209
SecondaryTime to First Dose of Rescue Medication for Sedation and Analgesia
Time frame:
6 to 24 hours
Reported as:
Median · Hours
Time to First Dose of Rescue Medication for Sedation and Analgesia
HoursDexmedetomidine Low DoseDexmedetomidine High Dose
Time to First Dose of Rescue Medication for Sedation and Analgesia1.6 (0.933 to 3.383)2.0 (1.067 to 3.750)
SecondaryTime to Successful Extubation
Time frame:
6 to 24 hours
Reported as:
Median · Hours
Time to Successful Extubation
HoursDexmedetomidine Low DoseDexmedetomidine High Dose
Time to Successful Extubation23.8 (18.550 to NA)20.5 (17.133 to 23.333)

Adverse events

Non-serious events are listed at a 1.1% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Dexmedetomidine Low Dose—1/89 (1.1%)48/89 (53.9%)
Dexmedetomidine High Dose—1/86 (1.2%)43/86 (50%)
Most frequent serious events
Most frequent serious events
EventDexmedetomidine Low DoseDexmedetomidine High Dose
ApnoeaRespiratory, thoracic and mediastinal disorders0/891/86
MyocarditisCardiac disorders1/890/86
Most frequent other events
Showing 10 of 92
Most frequent other events
EventDexmedetomidine Low DoseDexmedetomidine High Dose
HypokalaemiaMetabolism and nutrition disorders9/895/86
HypotensionVascular disorders4/897/86
PyrexiaGeneral disorders7/895/86
HypertensionVascular disorders7/890/86
AgitationPsychiatric disorders4/895/86
VomitingGastrointestinal disorders2/894/86
AtelectasisRespiratory, thoracic and mediastinal disorders3/894/86
BradycardiaCardiac disorders2/893/86
Oxygen saturation decreasedInvestigations1/893/86
Pleural effusionRespiratory, thoracic and mediastinal disorders2/893/86

Baseline characteristics

Age, Continuous
Age, Continuous(years)Dexmedetomidine Low DoseDexmedetomidine High DoseTotal
Mean2.35 ± 3.4372.85 ± 4.1722.60 ± 3.814
Age, Categorical
Age, Categorical(Participants)Dexmedetomidine Low DoseDexmedetomidine High DoseTotal
<=18 years8986175
Between 18 and 65 years000
>=65 years000
Age, Customized
Age, Customized(participants)Dexmedetomidine Low DoseDexmedetomidine High DoseTotal
>= 1 month to < 24 months6360123
>=24 months to < 17 years old262652
Sex: Female, Male
Sex: Female, Male(Participants)Dexmedetomidine Low DoseDexmedetomidine High DoseTotal
Female363874
Male5348101
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Dexmedetomidine Low DoseDexmedetomidine High DoseTotal
American Indian or Alaska Native336
Asian022
Native Hawaiian or Other Pacific Islander011
Black or African American141428
White6462126
More than one race112
Unknown or Not Reported7310
American Society of Anaesthesiologists (ASA) classification
American Society of Anaesthesiologists (ASA) classification(participants)Dexmedetomidine Low DoseDexmedetomidine High DoseTotal
P1 - Normal healthy patient (PT)358
P2 - PT w/ mild systemic disease281644
P3 - PT w/ severe systemic disease)5053103
P4 - PT w/ constant threat to life)81220
P5 - Moribund patient000
P6 - A declared brain-dead patient000
08

Study locations

37 sites
  • Maricopa Medical Center
    Phoenix, Arizona 85008, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Loma Linda University Medical Center, Pediatric Dept., Div. of Critical Care - PICU
    Loma Linda, California 92354, United States
  • Children's Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Pediatric Critical Care
    Los Angeles, California 90095, United States
  • Dept. of Anesthesia, SUMC
    Stanford, California 94305, United States
  • Children's National Medical Center
    Washington, District of Columbia 20010, United States
  • Joe Dimaggio Children's Hospital/Memorial Regional Hospital, Pediatric Intensive Care Unit
    Hollywood, Florida 33021, United States
  • Critical Care
    Jacksonville, Florida 32207, United States
  • University of Miami - Miller School of Medicine
    Miami, Florida 33136, United States
  • Miami Children's Hospital
    Miami, Florida 33155, United States
  • Orlando, Florida 32806, United States
  • Pensacola Research Consultants, Inc.
    Pensacola, Florida 32504, United States
  • University of Chicago Comer Children's Hospital
    Chicago, Illinois 60637, United States
  • Loyola University Medical Center
    Maywood, Illinois 60153, United States
  • Advocate Lutheran General Children's Hospital
    Park Ridge, Illinois 60068, United States
  • Kosair Charities Pediatric Clinical Research Unit, University of Louisville
    Louisville, Kentucky 40202, United States
  • The John Hopkins Medical Institutions, Anesthesia and Critical Care Medicine
    Baltimore, Maryland 21287-8711, United States
  • F3900 C.S. Mott Hospital SPC 5211 Dept. of Anaesthesiology
    Ann Arbor, Michigan 48109-5211, United States
  • Children's Hospital of Michigan
    Detroit, Michigan 48201, United States
  • Gilette Children's Speciality Healthcare
    Saint Paul, Minnesota 55101, United States
  • Montefiore Medical Center
    Bronx, New York 10467, United States
  • Duke University Medical Center, Department of Anesthesiology
    Durham, North Carolina 27710, United States
  • Akron Children's Hospital Medical Center
    Akron, Ohio 44308, United States
  • University Hospitals Case Medical Center
    Cleveland, Ohio 44106, United States
  • MetroHealth Medical Center
    Cleveland, Ohio 44109, United States
  • Northwest Pediatric Critical Care, P.C. Legacy Emanuel Children's Hospital
    Portland, Oregon 97227, United States
  • Children's Hospital of Pittsburgh of UPMC
    Pittsburgh, Pennsylvania 15224, United States
  • Medical University of South Carolina (MUSC)
    Charleston, South Carolina 29425, United States
  • Children's Medical Center Dallas
    Dallas, Texas 75235, United States
  • University of Virginia, Division of Pediatric Critical Care
    Charlottesville, Virginia 22908, United States
  • Virginia Commonwealth University
    Richmond, Virginia 23298-0530, United States
  • Madison, Wisconsin 53792, United States
  • BC Children's Hospital
    Vancouver, British Columbia V6H 3V4, Canada
  • Children's Hospital of Eastern Ontario
    Ottawa, Ontario K1H 8L1, Canada
  • Hospital for Sick Children
    Toronto, Ontario M5G 1X8, Canada
  • Pediatric Intensive Care Unit, CHU Sainte-Justine
    Montreal, Quebec H3T 1C5, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2010, a primary completion of Jan 2011 and a completion of Jan 2011. It does not say whether these dates are actual or estimated.

Results were first posted in Oct 2014, 3 years 9 months after primary completion. A results delay was requested in Jan 2012.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 31, 2009
First posted
Apr 3, 2009
Start
Jan 2010
Primary completionActual
Jan 2011
CompletionActual
Jan 2011
Results delay requested
Jan 4, 2012
Results first posted
Oct 30, 2014
Last update
Aug 14, 2015
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 14, 2015, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00875550
Responsible party
Sponsor
First posted
Apr 3, 2009
Start date
Jan 2010
Primary completion
Jan 2011
Completion
Jan 2011
Results posted
Oct 30, 2014
Last update
Aug 14, 2015

Study contacts

Robert Bilkovski, MD
study director · Medical Director, Hospira

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2015. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dexmedetomidine

Start the discussion